MCL

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients

Real-world Study of Acalabrutinib

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas